There are currently two approved FDA treatments for primary hyperoxaluria type 1, Lumasiran and Nedosiran, which target glycolate oxidase and lactate dehydrogenase respectively resulting in reduced endogenous oxalate synthesis 58
Not intended for general public promotion
Direct vendors usually focus on fast US delivery, and several also ship abroad, though customs rules differ by country
Br J Pharmacol 119(8):15331540 Mehta R, Pascual M, Soroko S, Savage B, Himmelfarb J, Ikizler T, Paganini E, Chertow G (2004) Spectrum of acute renal failure in the intensive care unit: the PICARD experience
Vital bodily functions can be impacted when glutathione levels are too low
human research : Most research has been conducted in rodents and small mammals, so it is not yet clear how these findings may translate to humans